Blar i Publikasjoner fra Cristin - St. Olavs hospital på forfatter "Jahnsen, Jørgen"
-
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Syversen, Silje Watterdal; Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sandanger, Øystein; Sexton, Joseph; Olsen, Inge Christoffer; Gehin, Johanna Elin; Warren, David; Brun, Marthe Kirkesæther; Klaasen, Rolf; Karlsen, Lars Normann; Noraberg, Geir; Zettel, Camilla; Ljoså, Maud-Kristine Aga; Haugen, Anne Julsrud; Njålla, Rune Johan; Bruun, Trude J; Seeberg, Kathrine; Michelsen, Brigitte; Strand, Eldri Kveine; Skorpe, Svanaug; Blomgren, Ingrid; Bragnes, Yngvill; Dotterud, Christian; Thune, Turid Jorunn; Ystrøm, Carl Magnus; Torp, Roald; Pawel, Mielnik; Mørk, Cato; Kvien, Tore Kristian; Jahnsen, Jørgen; Bolstad, Nils; Haavardsholm, Espen A. (Peer reviewed; Journal article, 2021)Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy ... -
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
Jørgensen, Kristin Kaasen; Goll, Guro Løvik; Sexton, Joe; Bolstad, Nils; Olsen, Inge C.; Asak, Øivind Wessel; Berset, Ingrid Prytz; Blomgren, Ingrid; Dvergsnes, Katrine; Florholmen, Jon; Frigstad, Svein Oskar; Henriksen, Magne; Hagfors, Jon; Huppertz-Hauss, Gert; Haavardsholm, Espen Andre; Klaasen, Rolf Anton; Moum, Bjørn; Noraberg, Geir; Prestegård, Ulf; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine; Torp, Roald; Vold, Cecilia; Warren, David J.; Ystrøm, Carl Magnus; Lundin, Knut Erik Aslaksen; Kvien, Tore Kristian; Jahnsen, Jørgen (Peer reviewed; Journal article, 2020)Background - The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease ...